FDA CONFIDENTIALITY CONCERNS PRECLUDE RESPONSES TO INDIVIDUAL PATIENT COMPLAINTS ABOUT DIFFICULTIES RECEIVING UNAPPROVED MEDICATIONS, HHS MAINTAINS
Executive Summary
FDA is unable to respond to patient complaints about access to medicines because of confidentiality concerns associated with the sponsors of the specific products in question, HHS maintained in a Sept. 22 letter to Rep. Barton's (R-Tex.) Commerce/Oversight Subcommittee.
You may also be interested in...
House Committee Watching Genasense; Show Of Force During FDA Review
The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011